F Dx Advisors, Inc. Editas Medicine, Inc. Transaction History

F Dx Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$26.55 - $40.57 $207,461 - $317,013	-7,814 Closed	0 $0
Q3 2021 Oct 08, 2021	SELL	$39.27 - $72.94 $41,076 - $76,295	-1,046 Reduced 11.81%	7,814 $321,000
Q2 2021 Aug 05, 2021	SELL	$31.29 - $56.64 $38,236 - $69,214	-1,222 Reduced 12.12%	8,860 $502,000
Q1 2021 Apr 14, 2021	BUY	$39.71 - $90.58 $383,558 - $874,912	9,659 Added 2283.45%	10,082 $423,000
Q1 2021 Apr 13, 2021	SELL	$39.71 - $90.58 $450,112 - $1.03 Million	-11,335 Reduced 96.4%	423 $17,000
Q4 2020 Feb 08, 2021	BUY	$27.07 - $84.35 $5,170 - $16,110	191 Added 1.65%	11,758 $824,000
Q3 2020 Nov 12, 2020	BUY	$28.06 - $37.16 $27,723 - $36,714	988 Added 9.34%	11,567 $325,000
Q4 2018 Feb 07, 2019	BUY	$18.19 - $31.79 $192,432 - $336,306	10,579 New	10,579 $241,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.